Business
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney diseaseVaroglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studiesStatistical evidence from meta-analysis of VIVIAD and VIVA-M
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update","length":96,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney disease","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"Varoglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studies","length":230,"tagName":"p"}]},{"val":[{"type":"text","content":"Statistical evidence from meta-analysis of VIVIAD and VIVA-MIND enables efficient design of Phase 2b study in diabetic kidney disease (DKD), ideally suited to evaluate varoglutamstat in the intended target population of stage 3b and worse, and to maximize probability of success in kidney disease","length":296,"tagName":"p"}]},{"val":[{"type":"text","content":"VIVIAD Phase 2b results of varoglutamstat on kidney function highlighted as late-breaking oral presentation at ASN Kidney Week in October 2024; varoglutamstat meta-analysis data accepted for oral presentation at ERA 2025 in June","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Pre-clinical data revealed synergistic effect of combination treatment with varoglutamstat and an SGLT2 inhibitor with both once and twice daily treatment","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Pursued stringent strategy for continued strengthening of IP around key assets; received notice of allowance for new varoglutamstat composition of matter patent in the U.S.","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered into Standby Equity Purchase Agreement (SEPA) of...